<DOC>
	<DOC>NCT02252536</DOC>
	<brief_summary>The purpose of this study is to determine whether gabapentin enacarbil is effective in the treatment of problems with alcohol.</brief_summary>
	<brief_title>HORIZANT (Gabapentin Enacarbil Extended-Release Tablets) for the Treatment of Alcohol Use Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Alcohol Drinking</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Gabapentin</mesh_term>
	<mesh_term>gamma-Aminobutyric Acid</mesh_term>
	<criteria>Subjects must meet each one of the following inclusion criteria in order to be eligible for participation in the study: 1. Be at least 21 years of age. 2. Have a current (past 12 months) DSM5 diagnosis of AUD. 3. Have a BAC by breathalyzer equal to 0.000 when s/he signed the informed consent document (either just prior to or immediately after signing consent). 4. Be seeking treatment for problems with alcohol. Additional will be evaluated in clinic. Evaluations will be conducted in clinic.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>alcohol use disorder</keyword>
	<keyword>alcoholism</keyword>
	<keyword>alcohol dependence</keyword>
	<keyword>drinking alcohol</keyword>
</DOC>